# AcuCort Sets November Rights Issue of Up to SEK 70.3 Million and Three-City Roadshow

> AcuCort's rights issue runs 12-26 November 2026 and may raise about SEK 70.3 million gross to fund FDA approval work for Zeqmelit and US market entry.

- Published: 2026-10-26T12:24:17+00:00
- Section: Funding
- Author: News Desk
- URL: https://newsforagent.com/news/2026-10-26/acucort-rights-issue-roadshow
- Source: [news.cision.com](https://news.cision.com/acucort-ab/r/acucort-to-hold-investor-roadshow-in-malmo--gothenburg-and-stockholm-in-connection-with-rights-issue,c4415149)

## Key takeaways

- AcuCort's rights issue runs from 12 to 26 November 2026 and may generate gross proceeds of approximately SEK 70.3 million if fully subscribed.
- CEO Jonas Jönmark and Strategic Alliance Manager Carl Frisk will present at investor meetings in Malmö, Gothenburg and Stockholm on 17-19 November 2026.
- Proceeds are intended to fund work towards FDA approval for Zeqmelit, US market entry preparations and commercial expansion in existing and new markets.

[AcuCort](https://akta.pro/company-profiles/00055y4/acucort) will hold investor roadshow meetings in Malmö, Gothenburg and Stockholm on 17-19 November 2026 in connection with a rights issue that may generate gross proceeds of approximately SEK 70.3 million if fully subscribed, [news.cision.com](https://news.cision.com/acucort-ab/r/acucort-to-hold-investor-roadshow-in-malmo--gothenburg-and-stockholm-in-connection-with-rights-issue,c4415149) said on October 26, 2026.

## AcuCort's November Rights Issue and Roadshow

CEO Jonas Jönmark and Carl Frisk, Strategic Alliance Manager, will present AcuCort's development, its international expansion and the upcoming rights issue at the meetings, followed by a Q&A session. The roadshow falls inside the subscription period, which runs from 12 to 26 November 2026. The SEK 70.3 million figure is stated before issue costs.

The proceeds are intended to be used, among other things, to fund AcuCort's continued work towards FDA approval for Zeqmelit®, preparations for market entry in the US and continued commercial expansion in existing and new markets. Zeqmelit® is currently sold in the Nordic region, and AcuCort has a commercial agreement with Glenmark Pharmaceuticals covering six European markets. AcuCort is finalising its NDA submission to the US Food and Drug Administration.

"We are at an important stage in AcuCort's development and look forward to the opportunity to meet both existing and potential shareholders. During the investor meetings, we will provide further insight into what we have achieved, our priorities going forward and how the rights issue will provide us with the resources to continue executing our strategy," Jönmark said.

## AcuCort's Funding and Partnership Record

According to akta.pro [company records](https://akta.pro/company-data), AcuCort has two funding rounds on record. A September 2026 grant of $15,330 was led by Region Skåne, and a June 2025 post-IPO equity round of $103,676 was led by Life Science Invest Fund. The same records list a January 2026 distribution partnership with Glenmark Pharmaceuticals covering Germany, the Netherlands, the Czech Republic, Austria, Slovakia and Ukraine, and a December 2025 order of EUR 112,000 from Unimedic Pharma covering the Nordic market with expected delivery in the second quarter of 2026.

| Funding round | Date | Amount | Lead investor |
| --- | --- | --- | --- |
| Post-IPO equity | June 2025 | $103,676 | Life Science Invest Fund |
| Grant | September 2026 | $15,330 | Region Skåne |

## Events Leading to the Rights Issue

AcuCort published a replay of its October 13 capital markets day presentation, covering international expansion in Europe and the US, The future of trading said in October 2026. The Europe strategy includes the Glenmark Pharmaceuticals commercial deal for six markets, with launches planned in 2027.

In September 2026, AcuCort received SEK 150,000 from Region Skåne to accelerate US commercial activities for Zeqmelit, matched by the company for a total budget of at least SEK 300,000, news.cision.com said. That same month, AcuCort's warrant programme for 2026-2029 was fully subscribed, with 1.5 million warrants transferred to four key personnel and 300,000 warrants reserved for future recruitment, each entitling the holder to subscribe for one share at SEK 1.34.

## Registration for the Investor Meetings

Registration for the three meetings is handled through AcuCort's [investor meetings page](https://acucort.com). Places are limited, and confirmation of attendance is sent by email.

## Companies in this story

- [AcuCort company profile](https://akta.pro/company-profiles/00055y4/acucort) · website: https://acucort.com

---
News for Agent · https://newsforagent.com/llms.txt